Ryan James Timothy Patrick 4
4 · BioNTech SE · Filed May 13, 2026
Research Summary
AI-generated summary of this filing
BioNTech (BNTX) CLO/CBO Ryan Patrick Receives Equity Awards
What Happened Ryan James Timothy Patrick, BioNTech's Chief Legal Officer and Chief Business Officer, was granted two equity awards on May 12, 2026. The filing shows 12,586 derivative shares as an option grant (exercise price €89.38) and 10,069 performance share units (PSUs), for a total of 22,655 derivative awards. These are grants (transaction code A) reported on a Form 4 and were filed the next day (May 13, 2026).
Key Details
- Date of grant: 2026-05-12; Form 4 filed 2026-05-13 (timely).
- Awards: 12,586 stock options (exercise price €89.38, subject to adjustment) and 10,069 PSUs.
- Vesting/exercisability: Options and PSUs vest annually in equal installments over four years beginning on the first anniversary; options become exercisable four years after grant, subject to performance and other conditions.
- Settlement: Awards may be settled in ordinary shares, ADSs and/or cash at the supervisory board’s election; each PSU is economically equivalent to one ordinary share and may vest based on performance versus the Nasdaq Biotechnology Index (or successor index).
- Shares owned after transaction: not specified in the excerpt provided.
- Filing timeliness: filed one day after the grant date; no late-filing indication in the provided data.
Context These were compensation awards, not open-market purchases or sales. Options have a specified strike (€89.38) and include an adjustment provision limiting ADS trading price to 800% of grant-date exercise price at exercise; PSUs are performance-based and only convert to value (shares/ADSs/cash) if performance targets and continued service are met. Such grants are routine executive compensation and do not by themselves signal immediate buying or selling of company stock.
Insider Transaction Report
- Award
Option (right to buy)
[F1][F2][F3]2026-05-12+12,586→ 12,586 totalFrom: 2030-05-12Exp: 2036-05-12→ Ordinary Shares (12,586 underlying) - Award
Performance Share Unit
[F4]2026-05-12+10,069→ 10,069 totalExercise: $0.00From: 2030-05-12Exp: 2036-05-12→ Ordinary Shares (10,069 underlying)
Footnotes (4)
- [F1]The exercise price of this option is EUR 89.38. Subject to adjustment such that the trading price of an American Depositary Share ("ADS") as of an exercise date does not exceed 800% of the grant date exercise price.
- [F2]The option vests annually in equal installments over four years commencing on the first anniversary of the grant date and becomes exercisable four years after the grant date, subject to certain performance-based and other conditions.
- [F3]The option may be settled in ordinary shares, ADSs and/or cash at the election of the supervisory board.
- [F4]Each performance share unit ("PSU") is the economic equivalent of one ordinary share of the Issuer and represents a right to receive, at the Issuer's option, one ordinary share, one ADS representing one ordinary share, or a cash payment or another form of settlement equal to the economic value thereof. PSUs vest annually in equal installments over four years commencing on the first anniversary of the grant date and become exercisable four years after the grant date, subject to the achievement of certain performance targets based on the market price of the Issuer's ordinary shares relative to the Nasdaq Biotechnology Index (or a comparable successor index) and the Reporting Person's continued service through each such date.